Canara Robeco Equity Hybrid Fund: change in investment factsheets for December 2022
![](https://portfolio.investmentguruindia.com/investmentguruimages/upload/post/2022/12/a175473860b5eccaf8656df6e10bc7d7.jpg)
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Canara Robeco Equity Hybrid Fund has announced change in investment factsheets and fund flash for the month ended December 15, 2022. As on Dec 15, 2022, the total size of the Fund was Rs 8,525.37 crores, compared with Rs 8,593.14 crores in the last month. The Fund's NAV per unit was Rs 252.88 for Growth, while 52-Week High and Low ranges were Rs 257.25 and Rs 218.87 respectively.
The Equity - Hybrid fund with Growth plan was launched on Feb 01, 1993 and managed by Fund Managers Shridatta Bhandwaldar, Ennette Fernandes, Avnish Jain. The top five companies based on a percentage of total holdings were ICICI Bank Ltd (546.64 Cr.), HDFC Bank Ltd (509.94 Cr.), Infosys Ltd (446.74 Cr.), State Bank of India (357.25 Cr.) and Axis Bank Ltd (311.47 Cr.). Canara Robeco Equity Hybrid Fund is promoted by Canara Robeco Mutual Fund and managed by Canara Robeco Asset Management Company Ltd..
![](https://portfolio.investmentguruindia.com/uploads/news/Apollo Hospitals_03july.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Shivam Thakral, CEO of BuyUcoin.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Manhar Garegrat_po.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Dilip Chenoy, Chairman, Bharat Web3 Association.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Titan Company_.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Indian Statergy_03july.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/coal37.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/ashwini37.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/Shrikant Chouhan.jpg)
![](https://portfolio.investmentguruindia.com/uploads/news/pharma.jpg)